Momelotinib, also known as Cyt387, is an ATP-competitive inhibitor of Janus kinases 1 and 2 (JAK1/JAK2). It is a benzamide derivative used as an active pharmaceutical ingredient in the production of treatments for myelofibrosis.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Cyt387?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Momelotinib dihydrochloride
pharmaceutical raw material
Momelotinib dihydrochloride monohydrate
pharmaceutical raw material
Acrivastine isomer Z
pharmaceutical raw material
(-)(3S,4R)-4-(4-fluorophenyl)-3-(3,4-methylenedioxy-phenoxymethyl)-N-benzylpiperidine hydrochloride
pharmaceutical raw material
Nateglinide
pharmaceutical raw material
Ent-Nateglinide
pharmaceutical raw material
4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoic acid
pharmaceutical intermediate
The international HS code for Cyt387 (CAS 1056634-68-4) is 2934.99.
2934.99
2934 99 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
ZVHNDZWQTBEVRY-UHFFFAOYSA-N
C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N
Sourcing Cyt387?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.